Pulse Biosciences CEO Paul LaViolette said at the Goldman Sachs healthcare conference that the company's nanosecond PFA technology is highly differentiated from standard systems, backed by 250 patents.
Pulse Biosciences (PLSE) presented at the Goldman Sachs 47th Annual Global Healthcare Conference on Wednesday, with CEO Paul LaViolette laying out the company's case in a crowded pulsed field ablation market.
LaViolette, who joined the company about 18 months ago, said what drew him was not PFA itself – the technology has become relatively standard – but Pulse's specific approach. The company uses nanosecond pulses, a form of nonthermal ablation that the CEO described as "highly differentiated" from the conventional microsecond PFA systems already on the market. Pulse holds 250 patents around that energy delivery mechanism.
The timing matters. PFA for cardiac ablation, especially atrial fibrillation, is one of the most competitive areas in medtech. Medtronic, Boston Scientific, and Johnson & Johnson all have approved or pending platforms. Differentiation is the only path to pricing power and adoption. LaViolette argued that Pulse's nanosecond waveform can treat a broader range of tissue types with less collateral damage, potentially expanding the addressable market beyond the heart into other soft-tissue applications.
The conference appearance gave Pulse a platform to make that case directly to institutional investors. The company is not yet generating significant revenue from its CellFX system, which is cleared for dermatologic use, and its cardiac candidate remains in clinical development. The bull case rests on the idea that nanosecond PFA will prove safer and more versatile than the competition, eventually commanding a premium in larger markets.
The bear case is that every PFA company claims differentiation, and the gap between preclinical data and commercial outcomes is wide. Pulse will need clinical data to back the claims. LaViolette acknowledged the landscape but stressed the patent portfolio and the team's deep device experience.
For investors tracking the medtech sector, the readthrough is straightforward: if Pulse's data holds up, it could become a niche player in a fast-growing procedure market. If competitors close the gap, Pulse's window could narrow. No timeline for new approvals was disclosed at the session.
Prepared with AlphaScala research tooling and grounded in primary market data: live prices, fundamentals, SEC filings, hedge-fund holdings, and insider activity. Each story is checked against AlphaScala publishing rules before release. Educational coverage, not personalized advice.